Merus N.V. Alternatives & Competitors
12 companies similar to Merus N.V. — Merus was acquired by Genmab. To see what’s new, visit Genmab.
Companies similar to Merus N.V.
Bright Biologics
Developing bispecific antibody drug to improve cancer treatment.
OncXerna Therapeutics
Advancing a new paradigm of precision oncology with a RNA-based approach to match patients...
Trillium Therapeutics Inc.
Clinical stage immuno-oncology company developing innovative therapies for the treatment o...
Lytix Biopharma
A clinical-stage immuno-oncology company developing proprietary oncolytic drugs as a novel...
Rival Readout
Competing with Merus N.V.? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Prescient Therapeutics
A clinical stage oncology company developing personalised medicine approaches to cancer; c...
2seventy bio
It’s about time we think smarter and faster than cancer.
Antharis Therapeutics, Inc.
Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting...
Xilio Therapeutics, Inc.
Focused on harnessing the immune system to achieve deep and durable clinical responses to...
Biotheus Inc.
To Inspire Each Other and Create Effective Medicines for Humankind
Immunitas Therapeutics
The Human Approach to Oncology
About Merus N.V.
Merus N.V., a biotechnology firm founded in 2003, is headquartered in The Netherlands. The company is at the forefront of developing innovative oncology solutions using its proprietary Biclonics® bispecific antibody therapeutics. This pioneering approach enables simultaneous multi-targeted tumor attacks, enhancing the...
Development of Cancer Treatments, Clinical Trials Management, Research and Development in Biotechnology, Multiclonics Therapeutics
Cancer Patients, Healthcare Providers, Medical Researchers, Pharmaceutical Industry
Biclonics®, Bispecific Antibody Therapeutics, Antibody-based Biopharmaceuticals, Oligoclonics Technology, Immuno-oncology, Cancer Treatment, Antibody Engineering, Tumor Cell Inhibition, Immune System Activation, Biomarker Development, Clinical Trials, Oncology Research, Therapeutic Antibodies, Antibody Discovery, Cell Biology
B2B, Platform, B2B2B
Product Sales, Licensing, Performance Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Merus N.V.: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Merus N.V. on 15 Jun 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.